Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Sarcoma, Kaposi 1Respiratory Distress Syndrome 1Pneumonia 1Multi-centric Castleman's Disease 1Hematologic Neoplasms 1Glioblastoma 1Castleman Disease 1Astrocytoma 1Acquired Immunodeficiency Syndrome 1

Interventions

liposomal doxorubicin 2Zidovudine 2Valganciclovir 2tocilizumab 1tanespimycin 1pomalidomide 1ibrutinib 1Vincristine 1Sirolimus 1Rituximab 1Prednisone 1Interferon-alpha 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Multi-centric Castleman's Disease × tocilizumab × Clear all
NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
8 enrolled 18 charts
LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon âš¡